70 related articles for article (PubMed ID: 7926970)
21. Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia.
Zinzani PL; Bendandi M; Magagnoli M; Albertini P; Rondelli D; Stefoni V; Tani M; Tura S
Haematologica; 2000 Nov; 85(11):1135-9. PubMed ID: 11064464
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
23. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
25. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zhu Y; Qin Q; Xie Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 38(3):221-4. PubMed ID: 23545817
[TBL] [Abstract][Full Text] [Related]
27. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Perkins JG; Flynn JM; Howard RS; Byrd JC
Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
[TBL] [Abstract][Full Text] [Related]
28. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ
Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936
[TBL] [Abstract][Full Text] [Related]
29. Is there a place for 2-CDA in the treatment of B-CLL?
Mitterbauer M; Hilgenfeld E; Wilfing A; Jäger U; Knauf WU
Leukemia; 1997 Apr; 11 Suppl 2():S35-7. PubMed ID: 9178836
[TBL] [Abstract][Full Text] [Related]
30. A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
Hocepied AM; Falkson CI; Falkson G
S Afr Med J; 1996 May; 86(5):549-50. PubMed ID: 8711555
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
Bergmann L; Fenchel K; Jahn B; Mitrou PS; Hoelzer D
Ann Oncol; 1993 May; 4(5):371-5. PubMed ID: 8353071
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
O'Brien ME; Matutes E; Cunningham D; Hill M; Emmett E; Ellis PA; Milan S; Hickish T; Mercieca J; Catovsky D
Leuk Lymphoma; 1994; 14 Suppl 2():17-23. PubMed ID: 7881347
[TBL] [Abstract][Full Text] [Related]
33. Oral fludarabine.
Plosker GL; Figgitt DP
Drugs; 2003; 63(21):2317-23. PubMed ID: 14524733
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Delfini C; Olivieri A; D'Adamo F; Leoni P
Tumori; 1995; 81(6):419-23. PubMed ID: 8804467
[TBL] [Abstract][Full Text] [Related]
35. Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Whelan JS; Davis CL; Rule S; Ranson M; Smith OP; Mehta AB; Catovsky D; Rohatiner AZ; Lister TA
Br J Cancer; 1991 Jul; 64(1):120-3. PubMed ID: 1713049
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporin A in the treatment of refractory B chronic lymphocytic leukemia (B-CLL).
Van Den Neste E; Maerevoet M; Martiat P; Ferrant A; Delannoy A; Michaux JL
Leukemia; 1995 Jun; 9(6):1102-3. PubMed ID: 7596177
[TBL] [Abstract][Full Text] [Related]
37. Chronic lymphocytic leukemia--correlation of response and survival.
Keating MJ; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Leuk Lymphoma; 1993; 11 Suppl 2():167-75. PubMed ID: 8124227
[TBL] [Abstract][Full Text] [Related]
38. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
Weiss RB; Freiman J; Kweder SL; Diehl LF; Byrd JC
J Clin Oncol; 1998 May; 16(5):1885-9. PubMed ID: 9586905
[TBL] [Abstract][Full Text] [Related]
39. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Di Raimondo F; Giustolisi R; Lerner S; Cacciola E; O'Brien S; Kantarjian H; Keating MJ
Ann Oncol; 2001 May; 12(5):621-5. PubMed ID: 11432619
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia.
Zinzani PL; Lauria F; Rondelli D; Benfenati D; Raspadori D; Bocchia M; Gozzetti A; Cavo M; Cirio TM; Zaja F
Eur J Haematol; 1993 Aug; 51(2):93-7. PubMed ID: 8370424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
